Kevin L Allen
Overview
Explore the profile of Kevin L Allen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2021 May;
16(5):e0252060.
PMID: 33999954
[This corrects the article DOI: 10.1371/journal.pone.0234268.].
2.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2020 Jun;
15(6):e0234268.
PMID: 32497150
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the vascular expression of anxA1 in specific...
3.
Li Q, Chan C, Peterson N, Hanna R, Alfaro A, Allen K, et al.
ACS Chem Biol
. 2020 Mar;
15(4):830-836.
PMID: 32155049
Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted delivery to tissues of interest. Systemic administration of lipid nanoparticle (LNP)-encapsulated mRNA leads to...
4.
Li Q, Peterson N, Hanna R, Kuszpit K, White J, Allen K, et al.
Mol Pharm
. 2019 Dec;
17(2):507-516.
PMID: 31841002
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for...
5.
Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert K, et al.
Bioconjug Chem
. 2019 Mar;
30(4):1232-1243.
PMID: 30912649
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of...
6.
Li Q, White J, Peterson N, Rickert K, Lloyd C, Allen K, et al.
J Control Release
. 2018 Apr;
279:126-135.
PMID: 29653224
The accumulation, dissemination and clearance of monoclonal antibody-based therapeutics or imaging reagents targeting tumor associated antigens is governed by several factors including affinity, size, charge, and valency. Tumor targeting antibody...
7.
Posokhova E, Wydeven N, Allen K, Wickman K, Martemyanov K
Circ Res
. 2010 Oct;
107(11):1350-4.
PMID: 20884879
Rationale: The parasympathetic reduction in heart rate involves the sequential activation of m2 muscarinic cholinergic receptors (m(2)Rs), pertussis toxin-sensitive (Gi/o) heterotrimeric G proteins, and the atrial potassium channel I(KACh). Molecular...
8.
Xie K, Allen K, Kourrich S, Colon-Saez J, Thomas M, Wickman K, et al.
Nat Neurosci
. 2010 May;
13(6):661-3.
PMID: 20453851
The type 5 G protein beta subunit (Gbeta5) can form complexes with members of the regulator of G protein signaling 7 (RGS7) family, but its relevance to neuronal G protein...
9.
Shakes L, Malcolm T, Allen K, De S, Harewood K, Chatterjee P
Nucleic Acids Res
. 2008 Oct;
36(19):6237-48.
PMID: 18832376
An enhancer within intron 1 of the amyloid precursor protein gene (APPb) of zebrafish is identified functionally using a novel approach. Bacterial artificial chromosomes (BACs) were retrofitted with enhancer traps,...